Patients with myelofibrosis can see their quality of life impacted in a range of ways with various symptoms, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Patients with myelofibrosis can see their quality of life impacted in a range of ways with various symptoms, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Transcript
What is the quality of life like for patients with myelofibrosis? How does it negatively impact them?
Quality of life in patients with myelofibrosis is really impacted in a range of ways. You know, first, they can have a degree of cytopenia-related difficulties. With anemia, they can have shortness of breath, fatigue, they can have thrombocytopenia, have increased risk of bruising, bleeding, etc.
Second, there's a whole range of what we believe are cytokine-related symptoms that they have from the disease. That can be inadvertent weight loss, night sweats, cachexia itching, things of that nature.
Third, if the counter high they can have vascular-related side effects: difficulties with headaches, concentration, complex migraines, etc.
Next, they may have potentially difficulties related to their spleen issues. Patients can sometimes have massive splenomegaly and with that they can have early satiety, they can kind of worse in that disease-associated weight loss, or they can have pain, discomfort, and derivative to these, they can have a lot of difficulties with insomnia and things of that nature.
It's really a whole range of things. Overall, we find that almost 90% of patients with myelofibrosis are symptomatic from their disease, some of them in a very severe way. And the individual pattern of symptoms is obviously somewhat unique to each patient.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Significant Disease Burden and Management Issues in Chronic Spontaneous Urticaria
April 15th 2025Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.
Read More